CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 526 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
LSN2839567
CAS:<p>LSN2839567 (Abemaciclib metabolite M2) is a CDK4 and CDK6 inhibitor with anticancer activity, inhibits CDK9, and can be used in breast cancer research.</p>Formula:C25H28F2N8Purity:99.14%Color and Shape:SolidMolecular weight:478.54(R)-(+)-O-Demethylbuchenavianine
CAS:(R)-(+)-O-Demethylbuchenavianine is a cyclin-dependent kinase (CDK) inhibitor. It inhibits CDK1, CDK5, glycogen synthase kinase 3 (GSK3), cdc2-like kinase (CLK1), and dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) with IC50 values of 1.1 μM, 0.95 μM, >10 μM, >10 μM, and >10 μM, respectively.Formula:C21H21NO4Color and Shape:SolidMolecular weight:351.40Riviciclib hydrochloride
CAS:Riviciclib hydrochloride (P276-00) is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Phase 2/3.Formula:C21H20ClNO5·HClPurity:99.51%Color and Shape:SolidMolecular weight:438.3XL413
CAS:XL-413 is an oral CDC7 kinase inhibitor, potentially blocking DNA replication, mitosis, and cancer cell growth.Formula:C14H12ClN3O2Purity:98.40% - 99.94%Color and Shape:SolidMolecular weight:289.72(S)-LY3177833 hydrate
CAS:(S)-LY3177833 ((S)-Example 2) hydrate, an orally active CDC7 kinase inhibitor, exhibits extensive in vitro anticancer efficacy.Formula:C16H14FN5O2Color and Shape:SolidMolecular weight:327.31Cdc7-IN-5
CAS:Cdc7-IN-5: potent Cdc7 serine-threonine kinase inhibitor, critical for starting DNA replication.Formula:C25H23N3O5Purity:98.4%Color and Shape:SolidMolecular weight:445.47CDK9-IN-14
CAS:CDK9-IN-14: Potent CDK9 inhibitor, IC50=6.92 nM, effective on MV-4-11 cells and in vivo tumors, low toxicity, minimal side effects.Formula:C21H23F2N3O4Color and Shape:SolidMolecular weight:419.42(S)-CR8
CAS:(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.Formula:C24H29N7OColor and Shape:SolidMolecular weight:431.53Cdc7-IN-17
CAS:Cdc7-IN-17 is a potent inhibitor of CDC7 with an IC 50 of <10 μM that can be used in cancer research [1].Formula:C13H15N5OSColor and Shape:SolidMolecular weight:289.36K 00546
CAS:K00546 inhibits CDK1/cyclin B (IC50: 0.6 nM), CDK2/cyclin A (IC50: 0.5 nM), CLK1 (IC50: 8.9 nM), and CLK3 (IC50: 29.2 nM).Formula:C15H13F2N7O2S2Purity:99.12%Color and Shape:SolidMolecular weight:425.44CDK8-IN-7
CAS:CDK8-IN-7 is a potent CDK8 inhibitor with a Kd of 3.5 nM, showing promise for AML research.Formula:C30H40N2Color and Shape:SolidMolecular weight:428.65Cdc7-IN-15
CAS:Cdc7-IN-15 (Example 108) is an inhibitor of cdc7 kinase that has potential to be used for cancer research [1].Formula:C12H14N4OSColor and Shape:SolidMolecular weight:262.33CP681301
CAS:CP681301 is a potent CDK5 inhibitor with anti-tumor effects in Drosophila and reduces Glioma stem cells' growth and renewal.Formula:C17H22N4OColor and Shape:SolidMolecular weight:298.38CCT068127
CAS:CCT068127 is a potent CDK2 and CDK9 inhibitor.Formula:C19H27N7OColor and Shape:SolidMolecular weight:369.46CDK4/6-IN-12
CAS:CDK4/6-IN-12 inhibits CDK4/6 with IC50s of 592.3 nM & 3090 nM, useful in cancer research.Formula:C12H10N6Color and Shape:SolidMolecular weight:238.25Cdc7-IN-9
CAS:Cdc7-IN-9 can be used for the research of cancer which is a potent inhibitor of Cdc7 [1].Formula:C15H17N5OSColor and Shape:SolidMolecular weight:315.39CDK7-IN-15
CAS:CDK7-IN-15, a pyrimidine-based potent CDK7 inhibitor, shows promise for various cancers with defective transcription.Formula:C21H24F4N6OSPurity:99.27%Color and Shape:SolidMolecular weight:484.51CDK7-IN-10
CAS:CDK7-IN-10: CDK7 inhibitor, IC50<100 nM, may hinder cell growth, induce apoptosis. (Patent WO2021016388A1, I-1)Formula:C29H35N7O3Color and Shape:SolidMolecular weight:529.63CDK7-IN-16
CAS:CDK7-IN-16, a potent CDK7 inhibitor (IC50: 1-10 nM), is used in cancer research with transcription defects.Formula:C19H21F3N6O2SColor and Shape:SolidMolecular weight:454.47ARN22089
CAS:<p>ARN22089 is an oral active CDC42 GTPase interaction inhibitor that blocks tumour growth in BRAF mutant mouse melanoma models and PDXs in vivo.</p>Formula:C23H27N5Purity:98.37%Color and Shape:SolidMolecular weight:373.49
